Jacksonville, FL Clinical Trials Report — July 2026

Jacksonville participants should act quickly if they match a study nearing its enrollment deadline: 40 recruiting trials are expected to close within the next 90 days, including 5 that accept healthy volunteers. Jacksonville also has 888 recruiting trials across 310 research facilities, so the immediate opportunity is less about finding any study and more about identifying the right local site before enrollment ends.

July brought 5 new trials, down from 18 in May and following 18 in February, 20 in March, 21 in April, and 19 in May. The city’s active research base remains large despite the slower pace of new openings.

Closing-soon studies create the most urgent opportunities

People considering research for stroke, skin disease, breast cancer, joint conditions, or other listed health issues should contact study teams now. Enrollment may end earlier than the projected date if a trial reaches its participant target.

• Stroke (3 closing trials)
• Ischemic stroke (2 trials)
• Atopic dermatitis (2 trials)
• Acute stress reaction (1 trial)
• Anatomic stage I breast cancer, AJCC v8 (1 trial)
• Anatomic stage II breast cancer, AJCC v8 (1 trial)
• Amputees, hip arthropathy, knee arthropathy, and arteriovenous fistula (1 trial each)

Healthy volunteers have 5 closing-soon options among these studies. Across Jacksonville overall, 60 trials are recruiting healthy volunteers. Screening rules differ and may include age, medications, medical history, or time-commitment requirements, so interested volunteers should ask sites whether they can still be evaluated before enrollment closes.

Notable Phase 2 and Phase 3 openings

The new-trial mix includes 4 drug studies, 1 dietary-supplement study, and 1 procedure study. The most prominent July additions include late-stage programs from Novo Nordisk and Axsome Therapeutics, as well as a Mayo Clinic cancer study.

• NCT07720271, Novo Nordisk’s Phase 3 AMAZE 9 study, is testing once-daily zenagamtide tablets for people with excess body weight. The study plans to enroll 950 participants and compares zenagamtide with placebo.
• NCT07717879, sponsored by Axsome Therapeutics, is a Phase 3 study evaluating solriamfetol in children ages 6 to under 12 with ADHD. Planned enrollment is 468 participants.
• NCT07717892 is a companion Axsome Therapeutics Phase 3 study of solriamfetol in adolescents ages 12 to under 18 with ADHD, also planning to enroll 468 participants.
• NCT07708961 is a Mayo Clinic Phase 2 study for EGFR-mutant, IDH-wildtype glioblastoma. It compares temozolomide alone with temozolomide plus WSD0922-FU and plans to enroll 60 participants.

New-study conditions include ADHD with 2 openings, along with glioblastoma, obesity, overweight, and sleep quality. One of the five new trials accepts healthy volunteers. The sponsor mix includes Axsome Therapeutics, Jacksonville University, Mayo Clinic, and Novo Nordisk. Three new studies are industry-sponsored and two are categorized as other.

Mayo Clinic sites dominate local access

Mayo Clinic facilities account for the largest concentration of recruiting studies in Jacksonville. Mayo Clinic in Florida leads with 157 trials, followed by several additional Mayo listings. Together, these sites offer especially broad access to oncology, neurology, metabolic health, and other specialty research.

• Mayo Clinic in Florida (157 trials)
• Mayo Clinic (73 trials)
• Mayo Clinic Florida (62 trials)
• Mayo Clinic Jacksonville (49 trials)
• Research Site (41 trials)
• Nemours Children’s Clinic-Jacksonville (33 trials)
• Baptist MD Anderson Cancer Center (22 trials)
• Jacksonville Center for Clinical Research (22 trials)
• Cancer Specialists of North Florida (15 trials)
• University of Florida (12 trials)

Families looking for pediatric opportunities should review Mayo and Nemours listings first. The two new ADHD studies are specifically designed for children and adolescents. Cancer patients may find the broadest range of options through Mayo Clinic, Baptist MD Anderson Cancer Center, and Cancer Specialists of North Florida.

Eligibility for families, women, and older adults

Among July’s new trials, 2 include children, 1 is female-only, and 2 include older adults. No new study is male-only. These categories describe trial eligibility at a high level; each study has additional requirements that may affect who can participate.

People without a diagnosed condition should not assume there are no options: Jacksonville has 60 healthy-volunteer trials currently recruiting. However, only one of the new July studies accepts healthy volunteers, while five closing-soon trials do. Healthy volunteers who are interested should prioritize screening calls now rather than waiting for additional summer openings.

Other Florida cities to consider

Participants willing to travel can broaden their search beyond Jacksonville. Miami has 15 recruiting trials in the nearby-city comparison, followed by Tampa with 13 and Orlando with 7. Coral Gables, Fort Myers, and Hollywood each have 5, while Miami Lakes has 4 and Fort Lauderdale has 3.

With the July opening rate lower than earlier in 2026, local enrollment windows may become more competitive for eligible participants. Checking Mayo Clinic and other high-volume Jacksonville facilities now—and widening the search to other Florida cities when travel is practical—can help patients and volunteers find opportunities before the next round of studies changes the local landscape.